ACE Inhibitors & ARBs - Pharmacology

1. This patient's clinical presentation is most likely mediated by the accumulation of which endogenous substance?
   Answer: Bradykinin ACE inhibitor-induced angioedema is a non-allergic, non-histaminergic reaction caused by the inhibition of kininase II (which is the same enzyme as ACE). This leads to the accumulation of bradykinin, a potent vasodilator that increases vascular permeability, resulting in angioedema. This adverse effect is more common in patients of African American descent. Histamine mediates Type I hypersensitivity reactions, while leukotrienes are involved in other inflammatory pathways.
2. The therapeutic effects of ARBs are mediated by blocking the AT1 receptor. During ARB therapy, angiotensin II levels increase and can stimulate the unblocked AT2 receptor. What is the generally accepted physiological consequence of AT2 receptor stimulation?
   Answer: Vasodilation, anti-proliferative, and pro-apoptotic effects. The AT1 receptor mediates most of the well-known detrimental effects of angiotensin II (vasoconstriction, aldosterone release, proliferation). The AT2 receptor, which is highly expressed in fetal tissue and re-expressed in pathological states, is thought to counteract the effects of the AT1 receptor. Stimulation of the AT2 receptor is associated with beneficial effects such as vasodilation (via nitric oxide), anti-proliferation, and apoptosis, which may contribute to the overall therapeutic benefit of ARBs.
3. A patient with hypertension is taking hydrochlorothiazide. Lisinopril is added to their regimen. The addition of lisinopril can potentiate the antihypertensive effect of hydrochlorothiazide and also mitigate which of its common adverse metabolic effects?
   Answer: Hypokalemia When you encounter questions about drug combinations, focus on how different mechanisms can work synergistically while addressing each other's side effects. This question tests your understanding of thiazide diuretics and ACE inhibitors working together. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that lowers blood pressure by promoting sodium and water excretion. However, thiazides also cause potassium loss because they block sodium reabsorption in the distal convoluted tubule, leading to increased potassium secretion. This hypokalemia is one of HCTZ's most clinically significant adverse effects. Lisinopril, an ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II. This reduces aldosterone production, which normally promotes potassium excretion. By decreasing aldosterone levels, lisinopril actually helps retain potassium, directly counteracting HCTZ's potassium-wasting effect. This makes D) hypokalemia the correct answer. Looking at the other options: A) Hyperuricemia occurs with thiazides because they compete with uric acid for excretion, but ACE inhibitors don't significantly affect uric acid levels. B) Hypercalcemia can occur with thiazides due to increased calcium reabsorption, but ACE inhibitors don't counteract this effect. C) Hyperglycemia is a thiazide side effect related to reduced insulin sensitivity, but ACE inhibitors have minimal impact on glucose metabolism. Remember this classic combination: thiazides waste potassium while ACE inhibitors spare it. This complementary relationship makes HCTZ + ACE inhibitor combinations extremely common in hypertension management, as they enhance efficacy while reducing the risk of dangerous electrolyte imbalances.
4. A patient is initiated on lisinopril for hypertension. After four weeks of consistent therapy, which set of changes in circulating hormone and peptide levels is most likely to be observed as a direct and indirect consequence of the drug's mechanism?
   Answer: Decreased angiotensin II, decreased aldosterone, increased renin, and increased bradykinin. Lisinopril inhibits ACE, which prevents the conversion of angiotensin I to angiotensin II. This leads to decreased angiotensin II levels and, subsequently, decreased aldosterone secretion. The reduction in angiotensin II removes negative feedback on the juxtaglomerular cells, leading to an increase in renin release. ACE is also known as kininase II, an enzyme that degrades bradykinin. Therefore, ACE inhibition leads to an accumulation (increase) of bradykinin.
5. A 60-year-old African American patient with newly diagnosed Stage 1 hypertension and no other comorbidities is being considered for antihypertensive monotherapy. According to major hypertension guidelines, which statement best describes the role of an ACE inhibitor as a first-line agent in this specific patient?
   Answer: It is generally less effective for blood pressure reduction compared to a thiazide diuretic or calcium channel blocker. When approaching hypertension treatment, you need to consider both patient demographics and guideline recommendations, as drug efficacy can vary significantly across different populations. The correct answer is D because major hypertension guidelines, including JNC 8 and AHA/ACC, specifically recognize that ACE inhibitors and ARBs tend to be less effective as monotherapy for blood pressure reduction in African American patients compared to thiazide diuretics or calcium channel blockers. This difference stems from the fact that African American patients more commonly have low-renin hypertension, making drugs that target the renin-angiotensin system less effective at lowering blood pressure. Choice A is incorrect because ACE inhibitors are not preferred first-line agents in African American patients - guidelines actually recommend thiazide diuretics or calcium channel blockers as preferred initial therapy. Choice B is wrong because beta-blockers are generally not recommended as first-line monotherapy for uncomplicated hypertension in any population due to inferior cardiovascular outcomes compared to other drug classes. Choice C overstates the risk - while ACE inhibitors can cause angioedema (which occurs more frequently in African Americans), the risk is not high enough to constitute a contraindication, and the primary issue here is efficacy, not safety. Study tip: Remember that hypertension treatment isn't one-size-fits-all. For pharmacology exams, know that African American patients typically respond better to thiazide diuretics and calcium channel blockers as first-line therapy, while ACE inhibitors/ARBs are more effective in Caucasian patients with high-renin hypertension.
6. The addition of this antibiotic to his current regimen creates a significant and acute risk for which life-threatening adverse event?
   Answer: Life-threatening hyperkalemia This patient is on multiple drugs that increase serum potassium: valsartan (an ARB) and spironolactone (a mineralocorticoid receptor antagonist). Trimethoprim, a component of the antibiotic, is known to act like the potassium-sparing diuretic amiloride by blocking the epithelial sodium channel (ENaC) in the distal nephron. This action severely impairs potassium excretion. The combination of these three agents presents a very high risk of developing severe, potentially fatal hyperkalemia.
7. Which of the following represents the most appropriate and safe initiation strategy for RAAS inhibition in this patient?
   Answer: Start ramipril at a very low dose, such as 1.25 mg daily, and recheck labs in 1-2 weeks. When you encounter questions about ACE inhibitor initiation in elderly patients with comorbidities, focus on the balance between therapeutic benefit and safety considerations. This patient has multiple factors requiring cautious dosing: advanced age, kidney disease, and borderline low blood pressure. The correct approach is D - starting ramipril at 1.25 mg daily with close monitoring. In elderly patients with CKD, ACE inhibitors provide cardiovascular and renal protection in HFrEF, but must be initiated cautiously. The reduced kidney function (eGFR 40) means slower drug clearance, and the borderline BP (105/65) leaves little room for hypotension. Starting low allows you to assess tolerance while minimizing risks of hyperkalemia, acute kidney injury, or symptomatic hypotension. The 1-2 week recheck is essential to monitor creatinine, potassium, and blood pressure. A is dangerous because 10 mg is too high an initial dose for this patient's profile - it could cause severe hypotension or acute kidney injury. B is overly conservative; while this patient has risk factors, ACE inhibitors are still beneficial in HFrEF with CKD when used carefully. The key is cautious initiation, not avoidance. C makes no sense - IV enalaprilat is for hypertensive emergencies, not routine HFrEF management, and would be extremely dangerous given her low-normal BP. Study tip: For elderly patients with CKD starting RAAS inhibitors, remember "start low, go slow, and follow closely." Always consider baseline kidney function and BP when determining starting doses, and plan early follow-up for safety monitoring.
8. A 68-year-old male is being discharged after an anterior wall myocardial infarction. His echocardiogram shows a left ventricular ejection fraction of 35%. His blood pressure is 110/70 mmHg and serum potassium is 4.2 mEq/L. The initiation of which medication is most critical for preventing adverse ventricular remodeling and reducing long-term mortality in this patient?
   Answer: Lisinopril In post-myocardial infarction patients with left ventricular systolic dysfunction (HFrEF), ACE inhibitors (or ARBs if ACEi-intolerant) are a cornerstone of therapy. They have been robustly shown to reduce mortality, decrease the risk of recurrent MI, and attenuate the process of adverse ventricular remodeling, where the ventricle dilates and changes shape, leading to progressive heart failure. Furosemide is for symptom control (congestion), while amlodipine and clonidine do not have this mortality benefit in post-MI HFrEF.
9. A 28-year-old female with chronic hypertension managed with enalapril informs you she is planning to conceive in the next few months. Her blood pressure is well-controlled. What is the most appropriate recommendation regarding her antihypertensive therapy?
   Answer: Discontinue enalapril and switch to an alternative agent such as labetalol or nifedipine. ACE inhibitors and ARBs are contraindicated in pregnancy (Category D) due to their teratogenic effects, including renal dysplasia, oligohydramnios, and skull hypoplasia, particularly in the second and third trimesters. Because organogenesis occurs early, it is recommended to switch to a safer alternative before conception. Labetalol, nifedipine, and methyldopa are preferred agents for managing hypertension during pregnancy. Switching to an ARB is incorrect as they carry the same teratogenic risk.
10. A 62-year-old male with HFrEF (EF 30%) and type 2 diabetes with proteinuria is evaluated for RAAS inhibitor therapy. His medical history is notable for a mild, non-pruritic, maculopapular rash that developed one month after starting ramipril several years ago; the rash resolved upon discontinuation. He has not taken an ACE inhibitor or ARB since. Which is the most appropriate next step in managing his RAAS blockade?
    Answer: Initiate valsartan at a low dose with careful monitoring. The correct answer is to initiate an ARB. While the prior rash may not have been a true allergy or class effect, the most prudent approach in a patient with a prior adverse reaction to an ACE inhibitor is to use an ARB. ARBs provide the same mortality and morbidity benefits in HFrEF and diabetic nephropathy without the same risk of cross-reactivity, as they have different chemical structures. Hydralazine/isosorbide dinitrate is a second-line option. Re-challenging with another ACE inhibitor, even a different one, carries an unnecessary risk of a recurrent reaction.
11. Beyond their roles in hypertension, heart failure, and diabetic kidney disease, ACE inhibitors have demonstrated a mortality benefit and reduction in cardiovascular events in which of the following patient populations?
    Answer: Patients with stable coronary artery disease but preserved left ventricular function. Large-scale clinical trials such as HOPE (using ramipril) and EUROPA (using perindopril) demonstrated that ACE inhibitors reduce the risk of myocardial infarction, stroke, and cardiovascular death in a broad range of high-risk patients with vascular disease (like stable CAD) or diabetes, even if they do not have hypertension or left ventricular dysfunction. This indicates a benefit related to plaque stabilization, endothelial function, and anti-atherosclerotic effects beyond simple blood pressure reduction.
12. Captopril is an ACE inhibitor that differs from enalapril and lisinopril in that it has a shorter half-life requiring more frequent dosing. It also contains a specific chemical group that is thought to be responsible for a higher incidence of which adverse effects?
    Answer: Sulfhydryl group causing rash and taste disturbances. Captopril contains a sulfhydryl (-SH) moiety, which is absent in most other commonly used ACE inhibitors (who are dicarboxylate-containing, like lisinopril, or phosphonate-containing, like fosinopril). This sulfhydryl group is associated with a higher incidence of specific side effects, including skin rash, taste disturbances (dysgeusia), and neutropenia, especially at higher doses. These side effects are less common with the non-sulfhydryl ACE inhibitors.
13. A patient with heart failure is treated with a maximal dose of an ACE inhibitor. Despite initial improvement, plasma levels of angiotensin II return to near-baseline levels after several months of therapy. This phenomenon is partially attributed to angiotensin II production via ACE-independent pathways. Why might an angiotensin II receptor blocker (ARB) still provide clinical benefit in this patient?
    Answer: ARBs block the AT1 receptor, inhibiting the effects of angiotensin II regardless of its synthesis pathway. The phenomenon described is often called 'ACE escape' or 'aldosterone escape'. Angiotensin II can be produced by alternative enzymes like chymase, particularly in cardiac tissue. An ACE inhibitor only blocks the ACE-mediated pathway. An ARB, however, works downstream by directly blocking the AT1 receptor. Therefore, it will inhibit the detrimental effects of angiotensin II whether it was produced by ACE or by an alternative pathway, making it potentially effective even when ACE inhibitor efficacy wanes.
14. A patient with type 2 diabetes and an eGFR of 25 mL/min/1.73m² is started on lisinopril for proteinuria. One week later, her serum creatinine rises from 2.4 mg/dL to 2.9 mg/dL (a ~21% increase). Which is the most appropriate interpretation and action?
    Answer: This is an expected hemodynamic effect; continue lisinopril with close monitoring of creatinine and potassium. Initiation of an ACE inhibitor or ARB often causes a small, self-limiting increase in serum creatinine (and decrease in eGFR) due to the beneficial reduction in intraglomerular pressure. A rise in creatinine of up to 30% from baseline is generally considered acceptable and is not a reason to stop the therapy, which provides long-term renal protection. The medication should be continued with ongoing monitoring. Discontinuation is only warranted for a rise >30%, progressive decline in renal function, or development of hyperkalemia.
15. This acute decline in renal function is most likely due to the ARB-induced inhibition of angiotensin II-mediated constriction of the:
    Answer: efferent arteriole. In patients with hemodynamically significant renal artery stenosis (often suspected in patients with widespread atherosclerosis), glomerular filtration rate (GFR) is highly dependent on angiotensin II-mediated constriction of the efferent arteriole. This constriction increases hydrostatic pressure within the glomerulus, maintaining filtration. By blocking this effect, an ACE inhibitor or ARB causes efferent arteriole dilation, leading to a precipitous drop in intraglomerular pressure and GFR, which manifests as a sharp rise in serum creatinine.
16. A clinician considers adding losartan to a patient's regimen of lisinopril to achieve a more complete RAAS blockade for diabetic nephropathy. Why is the dual therapy of an ACE inhibitor with an ARB generally not recommended by current clinical guidelines?
    Answer: Dual therapy does not offer additional mortality benefit and significantly increases the risk of hyperkalemia and acute kidney injury. Major clinical trials (e.g., ONTARGET) have shown that combining an ACE inhibitor and an ARB does not provide significant additional benefits in terms of mortality or major cardiovascular events compared to monotherapy. However, this combination is associated with a significantly higher rate of adverse events, including hyperkalemia, hypotension, and acute kidney injury. Therefore, dual RAAS blockade with an ACEi and ARB is contraindicated.
17. The combination of these medications places the patient at the highest risk for which of the following adverse events?
    Answer: Severe hyperkalemia This patient has multiple significant risk factors for developing severe hyperkalemia. Losartan (an ARB) decreases aldosterone production, spironolactone is a potassium-sparing diuretic, and ibuprofen (an NSAID) can impair renal function and reduce potassium excretion. The combination of these agents, particularly in a patient with pre-existing chronic kidney disease (Cr 1.8 mg/dL), creates a high risk for life-threatening hyperkalemia.
18. The primary therapeutic goal of using an ACE inhibitor in a normotensive patient with diabetic nephropathy is different from its goal in primary hypertension. Which of the following best describes this specific renal-protective mechanism?
    Answer: Preferential vasodilation of the efferent arteriole, reducing intraglomerular pressure. In diabetic nephropathy, hyperfiltration and increased intraglomerular pressure contribute to glomerular damage and proteinuria. Angiotensin II preferentially constricts the efferent arteriole. ACE inhibitors block angiotensin II production, leading to relatively more vasodilation of the efferent arteriole than the afferent arteriole. This reduces the hydrostatic pressure within the glomerulus, thereby decreasing proteinuria and slowing the progression of kidney disease, independent of the drug's effect on systemic blood pressure.
19. Compared to therapy with an ACE inhibitor like enalapril, treatment with an angiotensin II receptor blocker (ARB) like valsartan results in which distinct alteration of the renin-angiotensin system?
    Answer: Markedly higher circulating levels of angiotensin II. ARBs block the AT1 receptor, which prevents angiotensin II from exerting its effects. This interrupts the negative feedback loop on renin release. Consequently, plasma renin activity increases, leading to increased production of angiotensin I and subsequently angiotensin II. Because ARBs do not inhibit the ACE enzyme, this angiotensin II accumulates to high levels. In contrast, ACE inhibitors block the production of angiotensin II, leading to low levels.
20. What is the most critical safety consideration when making this therapeutic switch?
    Answer: The initial ARB dose should be 50% of the target dose to avoid hypotension. After ACE inhibitor-induced angioedema, switching to an ARB is generally safe as the risk of cross-reactivity is low (approximately 2-17% in studies). However, careful dose initiation is important as the patient may be more sensitive to blood pressure reduction. Starting with a lower dose and monitoring closely is the most practical safety consideration. While there is a small risk of angioedema recurrence with ARBs, this doesn't preclude their use, and no washout period is required when switching from ACE inhibitor to ARB.

Start this quiz